Printer Friendly
The Free Library
4,481,458 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Bigmar announces initial public offering.


COLUMBUS, Ohio--(BUSINESS WIRE)--June 20, 1996--Bigmar, Inc. today announced that the Securities and Exchange Commission yesterday declared effective its Registration Statement for an initial public offering of 1,400,000 shares of Common Stock. The Common Stock has begun trading today on The Nasdaq SmallCap Market under the symbol BGMR BGMR - Bigmar Inc. (stock symbol) and on The Boston Stock Exchange under the symbol BGM. The underwriters have a 45-day over-allotment option to purchase up to 210,000 additional shares of Common Stock from the Company.

The Common Stock was priced at $7.50 per share. Net proceeds to the Company of approximately $8.4 million will be used to acquire, test and/or manufacture oncological and biotechnological products; to repay debt; and for general corporate purposes, including working capital. LT Lawrence & Co., Inc. was the managing underwriter for the offering.

Bigmar, Inc. is currently engaged in manufacturing and marketing intravenous infusion solutions in Switzerland and Lichtenstein and marketing in Germany raw materials used to manufacture medications for the treatment of prostate enlargement and two generic oncological products, mercaptopurine mercaptopurine /mer·cap·to·pur·ine/ (6-MP) (mer-kap?to-pur´en) a sulfur-containing purine analogue, used as an antineoplastic and as an immunosuppressant.

mer·cap·to·pu·rine (mr-k
 and calcium leucovorin leucovorin /leu·co·vo·rin/ (-vor´in) folinic acid; the calcium salt is used as an antidote for folic acid antagonists, e.g., methotrexate, and in the treatment of megaloblastic anemias due to folic acid deficiency and colorectal carcinoma.

leu·co·vo·rin 
. Over the next 24 months, the Company's strategy is to manufacture, in its state-of-the-art facilities in Switzerland, and market generic oncological drugs. In addition, the Company is in the process of preparing to market certain licensed proprietary oncological and biotechnological products.

This announcement is neither an offer to sell nor a solicitation of an offer to buy any securities. Any such offer will be made only by means of a prospectus and only in those jurisdictions in which the making or acceptance thereof would be in compliance with the securities and Blue Sky laws of such jurisdictions. A written prospectus relating to the securities may be obtained from LT Lawrence & Co., Inc., 3 New York Plaza, New York, New York 10004 (212-361-6000).

CONTACT: Bigmar, Inc.

Gerald Sweeney, CFO

(614) 848-8380

-or-

Bigmar's Investor Relations Counsel

The Equity Group, Inc.

Tamara Ehlin

(212) 836-9607
COPYRIGHT 1996 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1996, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jun 20, 1996
Words:321
Previous Article:SCL anticipates proceeds in excess of $35 million from the sale of the two-way radio distribution business.
Next Article:CyberAmerica receives new symbol on OTC BB.
Topics:



Related Articles
BIGMAR, Inc. Discusses Restructuring Convertible Debt; Receives Compliance Notice From NASDAQ.
Bigmar Receives Product Approvals From the FDA.
BIGMAR Receives FDA Approval for Fluorouracil Injection; Sixth ANDA Approval in 1999.
Bigmar Announces 1998 Results.
BIGMAR Commences Proprietary Drug Development Strategy Via Licensing and Supply Agreement With Graminex.
Bigmar Announces 1999 First Quarter Results.
SWISS IKS APPROVES FORMULATION OF METRONIDAZOLE IN IV BAGS.(Brief Article)
BIGMAR GETS BRAZILIAN APPROVAL TO MARKET FLUOROURACIL.(Brief Article)
Selecting an attorney for your IPO.(initial public offering)(Brief Article)
Pricing and Performance of Initial Public Offerings in the United States.

Terms of use | Copyright © 2008 Farlex, Inc. | Feedback | For webmasters | Submit articles